Cargando…
Fecal S100A12 is associated with future hospitalization and step-up of medical treatment in patients with Crohn’s disease in clinical remission: a pilot study
BACKGROUND/AIMS: Fecal S100A12 (FS) and serum S100A12 (SS) have been reported as novel biomarkers that accurately reflect intestinal inflammation. We evaluated if FS and SS in comparison to fecal calprotectin (FC) are associated with poor future outcomes in clinically quiescent Crohn’s disease (CD)...
Autores principales: | Lee, Sun-Ho, Hwang, Sung Wook, Park, Sang Hyoung, Yang, Dong-Hoon, Byeon, Jeong-Sik, Myung, Seung-Jae, Yang, Suk-Kyun, Ye, Byong Duk |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Korean Association for the Study of Intestinal Diseases
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9081997/ https://www.ncbi.nlm.nih.gov/pubmed/35508954 http://dx.doi.org/10.5217/ir.2021.00020 |
Ejemplares similares
-
Elevated C-reactive protein level during clinical remission can predict poor outcomes in patients with Crohn’s disease
por: Oh, Kyunghwan, et al.
Publicado: (2017) -
Elevated C-reactive protein is associated with disease progression in patients with mild Crohn’s disease
por: Kwak, Min Seob, et al.
Publicado: (2016) -
Risk factors and prognostic value of acute severe lower gastrointestinal bleeding in Crohn’s disease
por: Yoon, Jiyoung, et al.
Publicado: (2021) -
Short-term tolerability and effectiveness of methotrexate monotherapy
in adult patients with Crohn’s disease: a retrospective study
por: Hong, Hee Seung, et al.
Publicado: (2021) -
Comparison of Concomitant Mesalamine and Immunomodulator Therapy and Immunomodulator Monotherapy for Crohn's Disease
por: Kwak, Min Seob, et al.
Publicado: (2018)